Book Lutetium-177 DOTA NOC Therapy 200 mCi at a diagnostic centre that is NABL- and NABH-certified. It is based on a radionuclide, Lutetium-177, linked to a molecule called DOTA-NOC, which is able to bind somatostatin receptors on many cells of neuroendocrine tumours. This allows for more effective delivery of radiation towards receptor-positive tumor sites and could help contain disease.

What is Lutetium-177 DOTA NOC Therapy?

Lutetium-177 DOTA NOC Therapy is a type of Peptide Receptor Radionuclide Therapy (PRRT) that can be given to specific patients with neuroendocrine tumours. For patients with disease that responds to imaging and expresses somatostatin receptors, the treatment could help slow tumour growth and manage the disease. After examining the patient's medical history, pertinent imaging, lab blood work, etc and/or the patient's kidney function, a treatment plan is formulated.

Common Reasons for Lutetium-177 DOTA NOC Therapy

• Treatment of selected patients with neuroendocrine tumours
• Management of somatostatin receptor-positive tumours
• Neuroendocrine tumours that have spread to other parts of the body
• Disease progression despite previous treatment
• Management of selected advanced or metastatic neuroendocrine tumours
• Patients considered suitable for peptide receptor radionuclide therapy after specialist evaluation

Conditions Evaluated Before Therapy

Somatostatin Receptor Expression

Imaging of somatostatin receptors can help evaluate if receptor expression is sufficiently high in tumour cells, e.g., by DOTA-NOC PET-CT. This is an important criterion for determining suitability for treatment.

Extent of Neuroendocrine Tumours

Imaging tests can aid in determining the extent of the disease and whether the tumour is likely to have invaded lymph nodes, bones, liver, or other organs.

Kidney Function

The radioactive substance is removed by the kidneys. Testing of kidney function is carried out prior to the treatment to ascertain if a patient is safe for the treatment.

Blood Cell Counts

Blood tests, including haemoglobin, white blood cell, and platelet counts, help assess bone marrow function and determine whether the patient can safely undergo treatment.

Overall Health Status

Prior to therapy, the patient's medical background, treatments, medication, and overall well-being are evaluated to see if the treatment is appropriate.

Why Choose Molecular Diagnostics and Therapy?

Patients built trust in Molecular Diagnostics and Therapy, an NABL- and NABH- accredited diagnostic centre that offers advanced nuclear radiology services. These services are supported by our experienced team and our team focuses on safety protocols, and proper care of the patients. Patients are guided by our specialists who are used to determine treatment suitability.

Book Lutetium-177 DOTA-NOC Therapy (200 mCi)

When expressing the need for DOTA-NOC Therapy (200 mCi) with Lutetium-177, you should consider Molecular Diagnostics and Therapy for patient-focused nuclear medicine care and professional evaluation. The history, the DOTA-NOC PET-CT scan, and the relevant laboratory reports are analyzed prior to determining the suitability for treatment. All therapy is administered by a competent nuclear medicine staff member and monitored with proper radiation safety measures and support after treatment.